OncoMed Pharma (OMED) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
OncoMed Pharmaceuticals (OMED) PT Lowered to $15 at Jefferies
May 6, 2016 8:03 AM EDTJefferies analyst Brian Abrahams kept a Buy rating but lowered his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $15.00 (from $16.00) following Q1 results.
Abrahams commented, "OMED's financials and clinical trial progress were mostly in line for the quarter, and while more key data... More
